Australia markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.1020+0.1020 (+3.40%)
As of 12:57PM EDT. Market open.
Full screen
Loading interactive chart…
  • GlobeNewswire

    Evaxion Announces Business Update and Full Year 2023 Financial Results

    Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines.Successful completion of initial phases of vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). MSD revealed as pharma partner for the EVX-B3 bacterial vaccine development program.Closing of $5.3 mi

  • Simply Wall St.

    When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?

    With the business potentially at an important milestone, we thought we'd take a closer look at Evaxion Biotech A/S...

  • GlobeNewswire

    Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

    The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes standard vaccine target discovery approaches and holds the promise of addressing serious unmet needsWith a unique modular architecture, AI-Immunology™ is scalable and adaptable towards partner needsThe potential of AI-Immunology™ is validated by established partnerships, including an ongoing vaccine c